Key clinical point: Reducing hyperuricemia with allopurinol improved endothelial function as measured by flow-mediated dilation.
Major finding: Allopurinol treatment was associated with a 4.2% absolute increase in flow-mediated dilation, a 41% relative increase from baseline.
Study details: SURPHER, a single-center crossover study with 82 participants completing the full protocol.
Disclosures: SURPHER received no commercial funding. Dr. Gaffo has received research funding from Amgen and AstraZeneca.
REPORTING FROM EULAR 2019 CONGRESS